Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NeoStem, Inc. (NYSE MKT: NBS) VSEL Funding Continued

VSELs might be an ideal cell therapy to regenerate the body's immune system and repair other tissues damaged by radiation exposure

NBS has been awarded the 2nd year of a 2 year grant totaling $595,252 for the Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) Stem Cells as a Countermeasure to Radiation Threat, Grant Number 5R43AI098325-02 from the NIAID, a division of the NIH.

The Bottom Line: This award funds studies to investigate the potential of very small embryonic-like stem cells as a countermeasure to radiological and nuclear threat. The award included $295,252 for the first year and $300,000 for the second year of the project. NBS expects to file an IND with the FDA in late 2013 or early 2014 to initiate a NIH funded human clinical study treating periodontitis with VSELs.

NBS closed at $0.69 with solid volume of 1.127 M shares as futures hold gains with a trading expectation +$0.01 to +$0.02 to drive the shares above $0.70. NBS is one company that has … GOOD news in the last few days.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.